Introduction
============

Strokes are reported to be the third leading cause of mortality following cancer and heart disease, and the most common cause of adult disability in developed countries ([@b1-mmr-15-04-2039]). It is estimated that 85% of strokes can be ascribed to atherosclerotic disease, and 10% are specifically associated with carotid atheroma ([@b2-mmr-15-04-2039],[@b3-mmr-15-04-2039]). Several factors have been identified to predispose to carotid atherosclerosis, including male gender, advancing age, hypercholesterolemia, systolic hypertension and obesity ([@b4-mmr-15-04-2039]). However, these classic characteristics are generally poor at predicting the risk of thromboembolism, which may lead to 80% needlessly exposed to the surgical risks of carotid endarterectomy ([@b5-mmr-15-04-2039]). Thus, it is important to investigate markers with improved ability in predicting the formation of carotid atheroma plaques.

With the emergence and improvement of gene microarray technology, global mRNA expression has been investigated for screening mRNA populations, which are differentially regulated in varied disease processes, and to provide clues to the underlying molecular pathology. In terms of carotid atheroma, a microarray study by Ayari and Bricca ([@b6-mmr-15-04-2039]) was performed in patients with significant carotid stenosis, and used for comparing gene expression between carotid plaque and intact arterial tissues. Expression profiling provides substantial valuable information, although the previous study focused on the gene expression of CD163 and HO-1 only, which suggested more pronounced induction of atheromatous plaque formation with these two genes. The deep mining of this set of data is urgently required as it is likely to assist in screening potential gene markers of carotid atheroma plaque formation.

In the present study the genome-wide expression profile of human carotid atheroma were analyzed comprehensively using high-throughput bioinformatics methods. Differentially expressed genes (DEGs) were identified in the carotid atheroma plaque and compared with the macroscopically intact carotid tissue adjacent to the atheroma plaque. Functional annotation and pathway enrichment were then performed, followed by the construction of protein-protein interaction (PPI) networks, analysis of key nodes and prediction of transcription factors (TFs). The aim of the present study was to examine potential gene markers for predicting the formation of carotid atheroma plaques.

Materials and methods
=====================

### Data source

The GSE43292 gene expression profile and its corresponding platform annotation files were downloaded from the Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>) ([@b7-mmr-15-04-2039]). This data set was submitted by Ayari and Bricca ([@b6-mmr-15-04-2039]) on 4th January 2013, last updated on 21st May 2015 and stockpiled on the GPL6244 platform (HuGene-1_0-st) Affymetrix Human Gene 1.0 ST Array \[transcript (gene) version\]). This gene expression data consisted of 32 paired samples of carotid atheroma plaque and macroscopically intact tissue adjacent to the atheroma plaque. Each paired sample was collected from sections obtained through carotid endarterectomy in one hypertensive patient. Specifically, the samples of the atheroma plaque were at stage IV or above according to the Stary classification ([@b8-mmr-15-04-2039]), and contained the core and shoulders of the plaque, whereas the other group of samples were distant macroscopically intact tissue at stages I and II.

### Data preprocessing

For the optimal mining of essential information from the gene expression profile, the raw level data were first preprocessed using the Robust Multi-array Average method in the Bioconductor oligo package (version 2.1; <http://www.bioconductor.org>), which is based on the Bioconductor principles of reproducibility, transparency and efficiency of development ([@b9-mmr-15-04-2039]). The probe ID for each gene was then converted to a gene symbol using the hugene10sttranscriptcluster.db, org.Hs.eg.db and annotate package in Biocondctuor (<http://www.bioconductor.org/>). For gene symbols corresponding to multiple probes IDs, the mean of these probes was calculated as the representative expression level of this gene.

### Screening for DEGs

To identify the DEGs between the carotid atheroma plaque and macroscopically intact carotid tissue samples, a paired t-test in the Linear Models for Microarray Data (LIMMA) package of R/Bioconductor software was performed for analyzing data from the gene expression experiments ([@b10-mmr-15-04-2039]). The Benjamini-Hochberg methods ([@b11-mmr-15-04-2039]) were further used to correct the P-value, and a false discovery rate of the P-value (FDP) was calculated ([@b12-mmr-15-04-2039]). FDP\<0.05 accompanied with \|log~2~ fold-change (FC)\| ≥0.58 were considered the thresholds for the identification of DEGs, which were grouped as upregulated and downregulated genes.

### Functional annotation and pathway enrichment

The Database for Annotation Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov>) is primarily used for functional annotation and classification. This tool was designed to systematically extract biological meanings from a large gene or protein list through a novel agglomeration algorithm ([@b13-mmr-15-04-2039]). To investigate the potential functions of the DEGs screened out above, DAVID was used to map the upregulated and downregulated genes to Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, respectively. The GO is determined using the Gene Ontology Consortium (<http://www.geneontology.org>) and widely used to produce a dynamic and controlled vocabulary for all eukaryotes with accumulation and alterations in gene and protein roles in cells ([@b14-mmr-15-04-2039]). To describe gene product attributes, GO provides three structured networks of defined terms, including cellular compartment (CC), biological process (BP) and molecular function (MF). By contrast, the KEGG pathway database (<http://www.genome.ad.jp/kegg>) contains information on how molecules or genes are networked, which is essentially a combined map of \~120 existing pathway maps ([@b15-mmr-15-04-2039]). In the present study, GO terms with a threshold of P\<0.05, and KEGG pathways with a threshold of P\<0.05 and enriched gene count ≥3 were selected.

### Construction of the PPI network

PPIs are considered to be important for understanding the potential functions of a certain protein, and the Search Tool for the Retrieval of Interacting Genes (STRING; <http://string-db.org/>) is designed to provide such a global perspective based on criteria, including experimental evidence, neighborhood, gene fusion, co-occurrence, co-expression, existing databases and text-mining ([@b16-mmr-15-04-2039]) In the present study, PPI pairs were predicted using STRING, and those with high confidence (PPI score \>0.07) were selected for construction of the PPI network. The PPI network was visualized using Cytoscape 2.8 (<http://cytoscape.org/>) ([@b17-mmr-15-04-2039]), followed by module analyses using ClusterONE with the threshold of \<4e-4. The genes in the significant modules were further mapped to KEGG pathways for functional analysis.

### Functional analysis for key nodes in the PPI network

Functional analyses were performed for key nodes in the PPI network constructed above. GenCLiP 2.0 is a web-based text-mining server, which can be used for the analysis of human genes with enriched keywords and molecular interactions (<http://ci.smu.edu.cn/GenCLiP2.0/confirm_keywords.php>). The Gene Cluster with Literature Profiles module in GenCLiP can annotate the input genes by generating statistically over-represented keywords based on the occurrence frequencies of free terms in gene-based literature. In addition, Agilent Literature Search software is a meta-search tool for automatically querying multiple text-based search engines to identify and extract associations among genes/proteins of interest (<http://www.agilent.com/labs/research/litsearch.html>). In the present study, the potential functions of key nodes in the PPI network were predicted using the Gene Cluster with Literature Profiles module with a threshold of P≤0.05 and Hit ≥6, and their associations with the formation of atheroma plaques were identified using Agilent Literature Search software with the key word 'atheroma plaque'.

### Prediction of TFs

iRegulon, as a Cytoscape plugin, was developed to reverse-engineer the transcriptional regulatory network underlying a co-expressed gene set using cis-regulatory sequence analysis and integrating databases of TFs, including Transfac, Jaspar, Encode, Swissregulon and Homer ([@b18-mmr-15-04-2039]). By setting the minimum identity between orthologous genes as 0.05 and the maximum false discovery rate on motif similarity as 0.001, iRegulon was used to predict TFs targeting to genes in the modules identified above with a normalized enrichment score \>5.

Results
=======

### Data processing and DEG screening

The profile normalization is shown in [Fig. 1A and B](#f1-mmr-15-04-2039){ref-type="fig"}. The median base-line level in the box plot indicates well-effected normalization. With the criteria of FDP\<0.05 and \|log2 FC\| ≥0.58, a total of 886 DEGs were finally screened out from the carotid atheroma plaque samples, when compared with those of the macroscopically intact carotid tissue, including 513 upregulated genes and 373 downregulated genes.

### Functional enrichment of DEGs

DAVID was used for predicting the potential functions of the DEGs by mapping the upregulated and downregulated genes to GO terms and the KEGG database, respectively. The top five significant GO terms of the MF, CC and BP categories enriched by the upregulated and downregulated genes, respectively, are shown in [Fig. 2](#f2-mmr-15-04-2039){ref-type="fig"}. The results demonstrated that the upregulated genes were predominantly associated with MFs, including carbohydrate binding, CCs, including plasma membrane and BPs, including immune response ([Fig. 2A](#f2-mmr-15-04-2039){ref-type="fig"}), whereas the downregulated genes were predominantly involved in MFs, including ion binding, CCs, including plasma membrane part and BPs, including cell adhesion ([Fig. 2B](#f2-mmr-15-04-2039){ref-type="fig"}). The results for the KEGG pathway enrichment are shown in [Fig. 3](#f3-mmr-15-04-2039){ref-type="fig"}, which indicated that the upregulated genes were significantly enriched in 24 pathways, including the chemokine signaling pathway and cytokine-cytokine receptor interaction ([Fig. 3A](#f3-mmr-15-04-2039){ref-type="fig"}); whereas the downregulated genes were predominantly involved in 13 pathways, including dilated cardiomyopathy and regulation of actin cytoskeleton ([Fig. 3B](#f3-mmr-15-04-2039){ref-type="fig"}).

### Construction of PPI network and functional analysis for key genes

The Cytoscape tool visually constructed the PPI network with 478 nodes and 1,457 edges, which were predicted using STRING with a PPI score \>0.07 ([Fig. 4](#f4-mmr-15-04-2039){ref-type="fig"}). In the PPI network, 35 nodes with a degree ≥20 were regarded as key genes ([Table I](#tI-mmr-15-04-2039){ref-type="table"}), among which only five were downregulated and the others were upregulated in the carotid atheroma plaque samples, compared with the macroscopically intact tissue samples adjacent to the atheroma plaque. Of the 35 key nodes, SYK, LYN and PIK3CG were the top three nodes, with degrees of 43, 43 and 37, respectively. The heat map indicated that these 35 genes were able to distinguish the two groups of tissue samples ([Fig. 5](#f5-mmr-15-04-2039){ref-type="fig"}). Literature mining using Gene Cluster with Literature Profiles revealed that these key nodes clustered in biological functions, which included phospholipase C, map kinase, cytokine production and inflammatory response ([Table II](#tII-mmr-15-04-2039){ref-type="table"}). The disease network was constructed with 296 nodes and 1,118 edges associated with the above 35 genes using Agilent Literature Search software ([Fig. 6](#f6-mmr-15-04-2039){ref-type="fig"}). Certain genes in this disease network were the DEGs identified above, indicating that these genes may be vital in the formation of atheroma plaques.

### Module analysis

In the PPI network, one module was mined using ClusterOne software with a threshold \<4e-4. A total of 29 DEGs, including 22 upregulated and seven downregulated genes, were used to construct this module and 11 TFs were predicted to target these genes by iRegulon ([Fig. 7](#f7-mmr-15-04-2039){ref-type="fig"}). The KEGG pathway enrichment showed that genes in this module were predominantly involved in the chemokine signaling pathway and cytokine-cytokine receptor interaction ([Table III](#tIII-mmr-15-04-2039){ref-type="table"}).

Discussion
==========

Strokes are one of the leading causes of mortality and long-time disability in the majority of countries worldwide ([@b19-mmr-15-04-2039]). Generally, a stroke is caused by an embolus or thrombus arising from a ruptured carotid atheromatous plaque or, more rarely, results from hemodynamic changes induced by the considerable contraction of the carotid lumen ([@b20-mmr-15-04-2039]). Strokes are described as being avoidable, however, a major challenge is identifying efficient markers to detect patients who are at risk of stroke. The present study aimed to investigate gene markers for predicting the formation of atheroma plaques by applying high throughput bioinformatics methods for comprehensive analyses of gene expression data from 32 paired samples of carotid atheroma plaque and macroscopically intact tissue adjacent to the atheroma plaque. A total of 886 DEGs, including 513 upregulated and 373 downregulated genes, were identified. This set of upregulated genes were predicted to be significantly involved in BPs, including carbohydrate binding and immune response, and were involved in 24 pathways. The downregulated genes were predominantly involved in ion binding and cell adhesion via 13 potential pathways. The PPI network constructed using these DEGs revealed 35 key nodes and one significant module. These results provided novel insight and valuable information for improving understanding the pathogenesis of carotid atheroma. Notably, key nodes in the PPI network and genes in the significant modules, including *SYK, LYN* and *PIK3CG*, are promising for the prediction of carotid atheroma plaque formation.

SYKis a 72 kDa non-receptor tyrosine kinase and its highest level expressed is in hematopoietic cells. SYK contains three functional domains, including two SRC homology 2 domains and a kinase domain (BOX 1). Investigations have focused on SYK as it is a potential therapeutic target in chronic inflammatory diseases, particularly in rheumatoid arthritis and asthma ([@b21-mmr-15-04-2039]). Apoptotic cell accumulation is a major feature of advanced human atherosclerotic lesions and is associated with increased susceptibility to thrombotic plaque complications ([@b22-mmr-15-04-2039]). A previous study reported that defective tyrosine kinase signaling in bone marrow cells may lead to the accumulation of apoptotic cells within atherosclerotic lesions, increase the proinflammatory immune response and accelerate atherosclerosis ([@b23-mmr-15-04-2039]). As a tyrosine kinase, SYK has also been found to be correlated with atherogenesis. Choi *et al* ([@b24-mmr-15-04-2039]) demonstrated that macrophage responses mediated by SYK may contribute to chronic inflammation in atherosclerosis in humans. Atherosclerotic lesions in low density lipoprotein-deficient mice, were examined following treatment with an SYK inhibitor, and were found to contain fewer macrophages, but more smooth muscle cells and collagen, which are features of more stable plaques in humans ([@b25-mmr-15-04-2039]). The SYK inhibitor, fostamatinib was identified as a potentially beneficial therapeutic strategy for patients with atherosclerosis as it was reported to reduce atherosclerotic lesion size by up to 59.6% in mice ([@b25-mmr-15-04-2039]). In the present study, the expression of SYK was found to be upregulated in the carotid atheroma plaque samples, compared with macroscopically intact tissue samples from the same hypertensive patient. Functional enrichment analysis revealed that SYK was associated with positive regulation of the immune system process and leukocyte activation, which was in accordance with the previous studies. Of note, SYK was characterized with the highest degree in the PPI network constructed of DEGs between the two sets of samples. Thus, it was hypothesized that SYK is a key factor in the process of carotid atherosclerosis and promising in the prediction of plaque formation.

LYN, also known as FYN, is a 59 kDa protein located on chromosome 6q21. LYN is also a member of the Src family of non-receptor tyrosine kinases. LYN is identified as a convergence point of several signaling pathways, and is vital in a number of BPs, including regulating cell cycle entry, growth, proliferation and cell-cell adhesion ([@b26-mmr-15-04-2039]). Using complementary inhibition strategies, Toubiana *et al* ([@b27-mmr-15-04-2039]) showed that LYN may be involved in nuclear factor (NF)-κB activation in human cellular models. Monocyte chemoattractant protein-1, as an inflammatory marker increased with arteriosclerosis, was found to be downregulated by inhibiting the activation of NF-κB, which is the vascular protective mechanism underlying the antihypertensive action of nifedipine ([@b28-mmr-15-04-2039]). In the present study, *LYN* was found to be differentially expressed in the carotid atheroma plaque samples and macroscopically intact tissue samples adjacent to the atheroma plaque from the same hypertensive patient, and as a key nodes in the PPI network constructed with using DEGs between these two groups. Therefore, this gene may be an essential marker in predicting plaque formation within the carotid artery.

*PIK3CG* encodes an enzyme, which can phosphorylate phosphoinositides. Single nucleotide polymorphisms (SNPs) close to or within *PIK3CG* have been shown to have important clinical significance. For example, the rs342286 SNP, located 140 kb upstream of the PIK3CG gene, may be associated with increased platelet aggregation and acute coronary syndromes ([@b29-mmr-15-04-2039]). A genome-wide association study by Wain *et al* ([@b30-mmr-15-04-2039]) on pulse pressure and mean arterial pressure demonstrated 7q22.3 close to *PIK3CG* as a novel pulse pressure locus, which may affect systolic blood pressure and diastolic blood pressure. In carotid artery plaques, a combined meta-analysis confirmed rs17398575, situated 96.5 kb from the *PIK3CG* gene, as the most significant signal, which may induce an 18% increase in chance of plaque presence ([@b31-mmr-15-04-2039]), although other reports do not support the association of this locus with subclinical atherosclerosis ([@b32-mmr-15-04-2039]). The results of the present study showed that *PIK3CG* was upregulated in carotid atheroma plaque samples, compared with macroscopically intact tissue samples from the same individual. It was also a key node in the PPI network with a relatively high degree. This suggested *PIK3CG* as one of key genes associated with the formation of carotid plaques.

Taken together, the DEGs identified in the carotid atheroma plaque samples, when compared with macroscopically intact tissue samples, may be involved in carotid atherogenesis. The key nodes identified in the PPI network constructed with these DEGs and genes involved in the significant module, including *SYK*, *LYN* and *PIK3CG*, are promising for the prediction of carotid plaque formation. Further experimental evidence is required to confirm these findings.

![Box plots for the expression profiles of microarray data (A) prior to normalization and (B) following normalization. The box refers to the quartile distribution (25--75%) range, with the median presented as a central black horizontal line in the box. The interval represents the minimum and maximum values, excluding outliers.](MMR-15-04-2039-g00){#f1-mmr-15-04-2039}

![GO analysis. (A) Upregulated genes and (B) downregulated genes. GO, Gene Ontology; MF, molecular function; CC, cellular component; BP, biological process.](MMR-15-04-2039-g01){#f2-mmr-15-04-2039}

![Pathway enrichment analysis. Pathway enrichment for (A) Upregulated genes and (B) downregulated genes.](MMR-15-04-2039-g02){#f3-mmr-15-04-2039}

![Protein-protein interaction network. Red circles represent upregulated genes and green circle represent downregulated genes. The lines represent the interaction between two nodes.](MMR-15-04-2039-g03){#f4-mmr-15-04-2039}

![Heat map for key nodes in the protein-protein interaction network. The scaled expression of the predicted key nodes, denoted as the row Z-score, is plotted in with a blue and brown color scale, with blue indicating high expression and sandy-brown indicating low expression.](MMR-15-04-2039-g04){#f5-mmr-15-04-2039}

![Protein-disease network constructed using Agilent Literature Search. The triangles represent the key nodes in the protein-protein interaction network, whereas pink circles and green circles represent the identified upregulated and downregulated genes, respectively. The blue circles represent other genes that were reported to be associated with this disease in scientific literature and other unstructured text. The grey lines indicate the interactions between two nodes.](MMR-15-04-2039-g05){#f6-mmr-15-04-2039}

![Significant modules in the protein-protein interaction network and predicted transcription factors targeting to genes in this module. The red and green circles represent the upregulated and downregulated genes identified in the study, respectively. The blue rhombi represent transcription factors. The dotted lines indicate the regulatory relationship between transcription factors and target genes. The solid grey line indicates the interaction between target genes.](MMR-15-04-2039-g06){#f7-mmr-15-04-2039}

###### 

Key nodes in the protein-protein interaction network with degrees ≥20.

  Gene symbol   Degree   Log~2~ fold-change
  ------------- -------- --------------------
  SYK           43       0.854037
  LYN           43       0.797114
  PIK3CG        37       0.721574
  VAV1          34       0.712220
  CXCR4         33       0.728104
  ICAM1         33       0.765050
  CCR2          32       0.671559
  MMP9          31       1.817924
  LPAR1         31       −0.648530
  CCR1          30       1.177328
  GNAI1         28       −0.624960
  FPR2          28       0.708739
  ITGAM         28       0.994177
  RAC2          27       0.871698
  CXCL10        26       1.046254
  PIK3R5        26       0.592723
  ADCY5         25       −0.936170
  ADCY7         25       0.611163
  CXCL16        24       0.708373
  HCK           24       0.789003
  ITGB2         24       0.967159
  FPR1          23       0.753358
  PTGER3        23       −0.600980
  CD4           23       0.926358
  CXCL2         22       0.581285
  CCL19         21       0.908325
  FPR3          21       0.815153
  PPARG         21       0.689479
  C5AR1         21       0.829772
  CCL21         21       0.620375
  HCAR3         20       0.580189
  C3AR1         20       0.676339
  PTPRC         20       0.782351
  FGR           20       0.767073
  NPY1R         20       −1.286510

###### 

Functional enrichment of key nodes in the protein-protein interaction network.

  Key word                      Hits (n)   P-value    Genes
  ----------------------------- ---------- ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#cluster1                                          
  Enrichment score: 48.42                             
    PHOSPHOLIPASE C             19         7.09E-47   C5AR1, CCR1, CD4, CXCR4, FGR, FPR1, FPR2, ICAM1, ITGAM, ITGB2, LPAR1, LYN, MMP9, PIK3CG, PTGER3, PTPRC, RAC2, SYK, VAV1
    MAP KINASE                  20         2.08E-51   C5AR1, CD4, CXCL10, CXCL2, CXCR4, FGR, FPR1, FPR2, ICAM1, ITGAM, ITGB2, LPAR1, LYN, MMP9, PIK3CG, PPARG, PTPRC, RAC2, SYK, VAV1
  \#cluster2                                          
  Enrichment score: 47.48                             
    CYTOKINE PRODUCTION         23         9.57E-76   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTGER3, PTPRC, SYK, VAV1
    INFLAMMATORY RESPONSE       24         2.28E-38   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, FPR2, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTGER3, PTPRC, RAC2, SYK
    TUMOR NECROSIS FACTOR       25         1.68E-30   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FGR, FPR1, FPR2, HCK, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTGER3, PTPRC, SYK
  \#cluster3                                          
  Enrichment score: 41.88                             
    CELL ADHESION               24         5.81E-23   C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, FPR2, HCK, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTPRC, RAC2, SYK, VAV1
    CELL ACTIVATION             26         2.95E-62   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FGR, FPR1, FPR2, HCK, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTPRC, RAC2, SYK, VAV1
  \#cluster4                                          
  Enrichment score: 37.67                             
  C REACTIVE PROTEIN            13         7.87E-13   C5AR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, FPR1, ICAM1, ITGAM, ITGB2, MMP9, PPARG, PTPRC
    TUMOR NECROSIS FACTOR       16         1.57E-48   C5AR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FGR, FPR1, ICAM1, ITGAM, ITGB2, MMP9, PIK3CG, PPARG, PTPRC
    HUMAN UMBILICAL VEIN        17         7.91E-54   C5AR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, FPR2, ICAM1, ITGAM, ITGB2, LPAR1, MMP9, PIK3CG, PPARG, PTPRC
  \#cluster5                                          
  Enrichment score: 32.27                             
    MONOCYTE                    18         8.99E-24   C5AR1, CCL19, CCL21, CCR1, CCR2, CD4,
    CHEMOATTRACTANT                                   CXCL10, CXCL16, CXCL2, CXCR4, FPR1, ICAM1,
    PROTEIN                                           ITGAM, ITGB2, MMP9, PIK3CG, PPARG, PTPRC
    MACROPHAGE                  18         2.13E-26   C5AR1, CCL19, CCL21, CCR1, CCR2, CD4,
    INFLAMMATORY                                      CXCL10, CXCL16, CXCL2, CXCR4, FPR1, ICAM1,
    PROTEIN                                           ITGAM, ITGB2, MMP9, PIK3CG, PPARG, PTPRC
    CENTRAL NERVOUS             19         1.87E-11   ADCY5, C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2,
    SYSTEM                                            CD4, CXCL10, CXCL2, CXCR4, FPR1, ICAM1, ITGAM, ITGB2, MMP9, PIK3CG, PPARG, PTPRC
    CELL ADHESION MOLECULE      20         6.56E-45   C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, ICAM1, ITGAM, ITGB2, MMP9, PIK3CG, PPARG, PTPRC, RAC2, SYK
    TOLL-LIKE RECEPTOR          21         1.87E-58   C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FPR1, FPR2, ICAM1, ITGAM, ITGB2, LYN, MMP9, PIK3CG, PPARG, PTPRC, SYK
  \#cluster6                                          
  Enrichment score: 28.75                             
    MITOGEN ACTIVATED PROTEIN   27         4.90E-39   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL2, CXCR4, FGR, FPR1, FPR2, HCK, ICAM1, ITGAM, ITGB2, LPAR1, LYN, MMP9, PIK3CG, PPARG, PTGER3, PTPRC, RAC2, SYK, VAV1,
    SIGNAL TRANSDUCTION         28         6.54E-20   C3AR1, C5AR1, CCL19, CCL21, CCR1, CCR2, CD4, CXCL10, CXCL16, CXCL2, CXCR4, FGR, FPR1, FPR2, HCK, ICAM1, ITGAM, ITGB2, LPAR1, LYN, MMP9, PIK3CG, PPARG, PTGER3, PTPRC, RAC2, SYK, VAV1

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment of genes in the significant module.

  Term                                                n     P-value    Genes
  --------------------------------------------------- ----- ---------- ---------------------------------------------------------------------------------------------------------------------
  hsa04062: Chemokine signaling pathway               17    2.23E-17   ADCY7, GNAI1, ADCY5, CCR1, CXCL2, CCL19, CCL8, CCL18, CXCL10, CCL13, ARRB2, CXCR4, ARRB1, CCL21, CXCL16, CCR2, GRK5
  hsa04060: Cytokine-cytokine receptor interaction    11    2.84E-07   CCL13, CCL21, CXCR4, CCR1, CXCL16, CXCL2, CCR2, CCL8, CCL19, CCL18, CXCL10
  hsa04080: Neuroactive ligand-receptor interaction     8   2.18E-04   C3AR1, C5AR1, PTGER3, FPR1, FPR3, FPR2, NPY1R, LPAR1
  hsa04540: Gap junction                                4   0.010074   ADCY7, GNAI1, ADCY5, LPAR1

[^1]: Contributed equally
